BioSpace News Archive

SELLAS Life Sciences Group, Inc. and GenFleet Therapeutics, Inc. announced that the companies have entered into an exclusive license agreement that grants rights to SELLAS for the development and commercialization of GFH009, a highly selective small molecule cyclin-dependent kinase 9 inhibitor, across all therapeutic and diagnostic uses worldwide outside of Greater China.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.

The Gastric Cancer Foundation has announced the launch of its 2022 grant program.

TransCode Therapeutics, Inc. today reported financial results for 2021 and recent business progress.

ImmunoGen, Inc. today announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for April 14, 2022 from 8:00 – 8:50am ET.

On March 31, 2022, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its annual results for the year ended December 31, 2021.

Albany NY, United States: Protein expression, purification and large scale production is achieved by manipulation in the gene expression process of an organism such that it is able to express large amounts of a recombinant gene.

Albany NY, United States: Renal cell carcinoma, also known as adenocarcinoma, refers to the cancer of kidneys in which malignant cells are found in the renal tubules.

Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes.

Rokote Laboratories Finland Ltd., a vaccine development company focussing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.